United Therapeutics Co. (NASDAQ:UTHR) Holdings Reduced by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 23.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 812 shares of the biotechnology company’s stock after selling 252 shares during the period. Capstone Investment Advisors LLC’s holdings in United Therapeutics were worth $291,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in UTHR. ClariVest Asset Management LLC raised its stake in United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in shares of United Therapeutics during the second quarter valued at about $30,000. Innealta Capital LLC acquired a new stake in United Therapeutics in the second quarter worth about $33,000. USA Financial Formulas bought a new position in United Therapeutics in the 3rd quarter valued at about $33,000. Finally, Brooklyn Investment Group bought a new stake in shares of United Therapeutics during the 3rd quarter worth about $33,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR opened at $370.49 on Friday. The firm has a 50 day simple moving average of $367.77 and a 200 day simple moving average of $335.19. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $417.82. The company has a market cap of $16.54 billion, a PE ratio of 16.27, a price-to-earnings-growth ratio of 1.08 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The company had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s revenue for the quarter was up 22.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.38 earnings per share. On average, equities analysts predict that United Therapeutics Co. will post 25.22 earnings per share for the current year.

Insider Activity at United Therapeutics

In other news, Director Judy D. Olian sold 1,750 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $412.48, for a total value of $721,840.00. Following the sale, the director now owns 5,655 shares of the company’s stock, valued at approximately $2,332,574.40. This represents a 23.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO James Edgemond sold 7,802 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the sale, the chief financial officer now directly owns 3,210 shares of the company’s stock, valued at $1,108,766.10. This represents a 70.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 127,227 shares of company stock valued at $47,398,820. Corporate insiders own 11.90% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on UTHR. Wells Fargo & Company increased their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a report on Tuesday, August 20th. HC Wainwright increased their price target on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. The Goldman Sachs Group raised their target price on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Finally, Argus boosted their price target on shares of United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.